Join us for an insightful webinar exploring cutting-edge advancements in blood-based biomarker research for neurodegenerative diseases. Dr. Maura Malpetti and Dr. Sterling Johnson will present novel findings leveraging Alamar Biosciences' highly sensitive NULISA™ immunoassay technology. This session will cover how multiplex proteomic analysis is unlocking new insights into Alzheimer’s disease (AD) and other neurodegenerative disorders, providing crucial data for early detection, differential diagnosis, and disease monitoring. The discussion will highlight Cambridge-based cohorts as well as the Wisconsin Registry for Alzheimer’s Prevention (WRAP) study, showcasing how blood biomarkers, including pTau, NfL, and inflammation markers, are reshaping our understanding of AD progression, multi-etiology dementia, and survival prediction.

Dr. Malpetti will discuss the role of inflammation and neurodegeneration in diseases beyond AD, including frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). Meanwhile, Dr. Johnson will delve into the challenges of identifying mixed-pathology dementia and how emerging biomarker tools enhance precision medicine approaches. Attendees will gain insights into the translational impact of large-scale proteomic screening, the integration of blood-based markers with imaging modalities, and the future of biomarker-driven clinical trials. Additionally, Doug Hinerfeld, Sr. Director of Field Application Support, will provide an overview of Alamar’s innovative NULISA technology and its role in accelerating discoveries in neurodegenerative research.